Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC9A1 | P19634 | 1/20 | 0.35 |
| ▸ | TOP2A | P11388 | 1/20 | 0.34 |
| ▸ | TDO2 | P48775 | 10/20 | 0.33 |
| ▸ | IDO1 | P14902 | 8/20 | 0.33 |
| ▸ | GRM5 | P41594 | 1/20 | 0.32 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | MAP3K5 | Q99683 | 1/20 | 0.30 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22643744 | 0.95 | SLC9A1 (0.35) | SLC9A1TOP2ATDO2IDO1GRM5 | |
| SCHEMBL20693319 | 0.91 | SLC9A1 (0.34) | SLC9A1TOP2ATDO2IDO1MEN1 | |
| SCHEMBL20822255 | 0.91 | SLC9A1 (0.38) | SLC9A1TOP2ATDO2IDO1GRM5 | |
| SCHEMBL24974789 | 0.91 | SLC9A1 (0.34) | SLC9A1TOP2ATDO2IDO1MEN1 | |
| SCHEMBL19170430 | 0.86 | GRM5 (0.34) | SLC9A1TOP2ATDO2IDO1GRM5 | |
| SCHEMBL27269724 | 0.86 | SLC9A1 (0.38) | SLC9A1TOP2ATDO2IDO1GRM5 | |
| SCHEMBL17992585 | 0.85 | MAP3K5 (0.37) | TOP2AGRM5GRM1MEN1ALDH1A1 | |
| SCHEMBL23799155 | 0.84 | TDO2 (0.33) | TDO2IDO1GRM5GRM1ALDH1A1 | |
| SCHEMBL21618442 | 0.84 | TOP2A (0.39) | TOP2ATDO2IDO1GRM5GRM1 | |
| SCHEMBL21152799 | 0.84 | MAP3K5 (0.34) | GRM5GRM1MEN1ALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240066133-A1 | THERAPEUTIC AGENTS AND CONJUGATES THEREOF | AJ SCIENCES (YIXING) CO., LTD (CN) | 2024-02-29 | — | — | US | disclosed |
| US-11760775-B2 | Steroids and protein-conjugates thereof | REGENERON PHARMACEUTICALS, INC. | 2023-09-19 | — | — | US | disclosed |
| US-11572370-B2 | CD16A binding agents and uses thereof | BIOHAVEN THERAPEUTICS LTD. (US) | 2023-02-07 | — | — | US | disclosed |
| US-20220401561-A1 | PROTEIN-MACROMOLECULE CONJUGATES AND METHODS OF USE THEREOF | AJ SCIENCES (YIXING) CO., LTD (CN) | 2022-12-22 | — | — | US | disclosed |
| US-20220175946-A1 | CONDITIONING METHODS FOR GENE THERAPY | REGENERON PHARMACEUTICALS, INC. | 2022-06-09 | — | — | US | disclosed |
| US-20210332080-A1 | HYDROPHILIC LINKERS FOR ANTIBODY DRUG CONJUGATES | REGENERON PHARMACEUTICALS, INC. | 2021-10-28 | — | — | US | disclosed |
| US-20210040144-A1 | STEROIDS AND PROTEIN-CONJUGATES THEREOF | REGENERON PHARMACEUTICALS, INC. | 2021-02-11 | — | — | US | disclosed |
| US-20200353076-A1 | ANTI-FOLATE RECEPTOR ALPHA ANTIBODY CONJUGATES AND THEIR USES | SUTRO BIOPHARMA, INC. | 2020-11-12 | — | — | US | disclosed |
| US-20200255523-A1 | FC SILENCED ANTIBODY DRUG CONJUGATES (ADCS) AND USES THEREOF | REGENERON PHARMACEUTICALS, INC. | 2020-08-13 | — | — | US | disclosed |
| US-10711032-B2 | Steroids and protein-conjugates thereof | REGENERON PHARMACEUTICALS, INC. (US) | 2020-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210332080-A1 | HYDROPHILIC LINKERS FOR ANTIBODY DRUG CONJUGATES | CD44, CD47, EPCAM | SLC9A1 1849/4885TOP2A 594/4885TDO2 3477/4885 |
| US-20200353076-A1 | ANTI-FOLATE RECEPTOR ALPHA ANTIBODY CONJUGATES AND THEIR USES | FOLR2, FOLR1, FCGRT | SLC9A1 1103/4885TOP2A 1159/4885TDO2 2188/4885 |
| US-20200255523-A1 | FC SILENCED ANTIBODY DRUG CONJUGATES (ADCS) AND USES THEREOF | FCGR1A, FCGR2A, FCGR3B | SLC9A1 1511/4885TOP2A 4481/4885TDO2 2784/4885 |
| US-10711032-B2 | Steroids and protein-conjugates thereof | SERPINA6, NR3C1, NR3C2 | SLC9A1 4610/4885TOP2A 1915/4885TDO2 4638/4885 |
| US-20220175946-A1 | CONDITIONING METHODS FOR GENE THERAPY | CD74, CD2, CD44 | SLC9A1 399/4885TOP2A 2367/4885TDO2 3308/4885 |
| US-20220401561-A1 | PROTEIN-MACROMOLECULE CONJUGATES AND METHODS OF USE THEREOF | CD44, SSB, DNPEP | SLC9A1 4649/4885TOP2A 773/4885TDO2 4218/4885 |
| US-11572370-B2 | CD16A binding agents and uses thereof | FCGR1A, FCGR2A, FCGR3B | SLC9A1 3180/4885TOP2A 3396/4885TDO2 4732/4885 |
| US-20210040144-A1 | STEROIDS AND PROTEIN-CONJUGATES THEREOF | SERPINA6, NR3C1, NR3C2 | SLC9A1 4609/4885TOP2A 1745/4885TDO2 4647/4885 |
| US-20240066133-A1 | THERAPEUTIC AGENTS AND CONJUGATES THEREOF | TLR9, STING1, TLR3 | SLC9A1 2140/4885TOP2A 41/4885TDO2 1800/4885 |
| US-11760775-B2 | Steroids and protein-conjugates thereof | SERPINA6, NR3C1, NR3C2 | SLC9A1 4609/4885TOP2A 1745/4885TDO2 4647/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.